The prevalence of recurrent spontaneous abortions cancer, and congenital anomalies in the families of couples with recurrent spontaneous abortions or gestational trophoblastic tumors

1991 ◽  
Vol 165 (2) ◽  
pp. 461-466 ◽  
Author(s):  
Hong-Nerng Ho ◽  
Thomas J. Gill ◽  
Chang-Yao Hsieh ◽  
Yu-Shih Yang ◽  
Tzu-Yao Lee
Keyword(s):  
Congenital Anomalies ◽  
Spontaneous Abortions ◽  
Recurrent Spontaneous Abortions ◽  
Trophoblastic Tumors

Immunogenetic and serological investigations in nonpregnant and in pregnant women with a history of recurrent spontaneous abortions

1994 ◽  
Vol 27 (2) ◽  
pp. 95-109 ◽  
Author(s):  
Gertrud Mueller-Eckhardt ◽  
Peter Mallmann ◽  
Jürgen Neppert ◽  
Annette Lattermann ◽  
Anette Melk ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Spontaneous Abortions ◽  
Recurrent Spontaneous Abortions ◽  
History Of

Fetal Minoxidil Exposure

PEDIATRICS ◽  
1987 ◽  
Vol 80 (1) ◽  
pp. 120-120
Author(s):  
FRANZ W. ROSA ◽  
JUHANA IDANPAAN-HEIKKILA ◽  
RITA ASANTI
Keyword(s):  
Case Report ◽  
Drug Administration ◽  
Birth Defects ◽  
Drug Safety ◽  
Congenital Anomalies ◽  
Drug Exposure ◽  
Spontaneous Abortions ◽  
Multiple Congenital Anomalies ◽  
Exposure Data ◽  
National Drug

To the Editor.— Kaler et al (Pediatrics 1987;79:434-436) provided a case report of hypertrichosis and multiple congenital anomalies with maternal minoxidil use. Reports such as this contribute to alerting national drug safety offices of possible teratologic questions. Maternal drug exposure data, since 1979 when minoxidil was marketed, is available to the Food and Drug Administration (FDA) from 73,000 pregnancies (15,600 birth defects, 4,400 spontaneous abortions, and 53,000 normal outcomes). This yields, in addition to the report by Kaler et al, only two other births with maternal minoxidil exposures:

Sign in / Sign up

Export Citation Format

Share Document